AstraZeneca Pharma India Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

The AstraZeneca Pharma India share price target for 2026 stands at Rs 11200 as per the latest analyst forecast, implying 27 percent upside from the current market price of Rs 8800. Investors tracking the AstraZeneca Pharma India share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings timeline, key risks, and the bull vs bear case scenarios. This article covers every dimension of the AstraZeneca Pharma India share price target thesis updated April 2026.

Click Here to Get Free Investment Predictions on Univest

Track live AstraZeneca Pharma India price, FII or DII flows and analyst targets on the Univest Screener.

AstraZeneca Pharma India Company Overview

Tap to Access Best Research on Univest

AstraZeneca Pharma India (NSE: ASTRAZEN) is a listed company in India’s Pharma sector with a market capitalisation of Rs 18530 crore. At CMP Rs 8800 against a 52 week range of Rs 7400 to Rs 10200, the stock currently offers meaningful upside to the analyst price forecast of Rs 11200. For more share price target analysis, visit Univest Blogs.

Parameter	Value
NSE Ticker	ASTRAZEN
Sector	Pharma
CMP April 2026	Rs 8800
52 Week High	Rs 10200
52 Week Low	Rs 7400
Market Cap	Rs 18530 crore
Trailing P/E	48x
12M Analyst Price Forecast	Rs 11200
Bull Case Target	Rs 13400
Bear Case Target	Rs 6720

Why Analysts Set the AstraZeneca Pharma India Share Price Target at Rs 11200 for 2026

FY27 Earnings Delivery and Revenue Acceleration

FY27 is the key year where analysts expect AstraZeneca Pharma India to deliver meaningful PAT growth. This is the primary variable that bridges the gap between the current CMP of Rs 8800 and the AstraZeneca Pharma India share price target 2026 of Rs 11200. Analysts project 15 to 20 percent PAT growth in FY27. Track Q4 results live on the Univest Screener.

Sustained domestic demand from rising incomes

Sustained domestic demand from rising incomes is a key growth driver that analysts highlight in supporting the AstraZeneca Pharma India share price target of Rs 11200. The Pharma sector is expanding at 12 to 18 percent annually, and AstraZeneca Pharma India is well-positioned to capture a rising share. Discover top Pharma stocks on the Univest Screener.

Global supply chain realignment favouring India

Global supply chain realignment favouring India provides an additional lever that can help AstraZeneca Pharma India exceed analyst projections and potentially push the stock toward the bull case target of Rs 13400. Compare AstraZeneca Pharma India with sector peers on the Univest Screener.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s rate cut cycle that commenced in 2026 reduces AstraZeneca Pharma India’s borrowing costs and stimulates end-market demand, supporting the AstraZeneca Pharma India share price target 2026 of Rs 11200.

Union Budget 2026-27 Policy Support

Budget 2026-27 capex continuity and PLI scheme extensions create a constructive backdrop for AstraZeneca Pharma India’s Pharma business, directly supporting the AstraZeneca Pharma India share price target 2026 bull case of Rs 13400.

Bull Case, Base Case and Bear Case for AstraZeneca Pharma India Share Price Target

Scenario	Target	Key Assumption
Bull Case	Rs 13400	FY27 revenue growth exceeds 25 percent, margin expansion of 200 bps, sector re-rating
Base Case Forecast	Rs 11200	FY27 revenue growth of 15 to 18 percent, stable margins, current P/E sustained
Bear Case	Rs 6720	Revenue growth disappoints below 10 percent, margin pressure, valuation de-rating

For live tracking of AstraZeneca Pharma India analyst price targets and ratings, use the Univest Screener.

Key Risks to the AstraZeneca Pharma India Share Price Target

Earnings Miss Risk

If AstraZeneca Pharma India reports quarterly earnings below expectations, the AstraZeneca Pharma India share price target will likely face downward revision. Watch Q4 FY26 results closely on Univest Screener.

Macro and Global Headwinds

The US 26 percent reciprocal tariff announcement of April 2026 has created global macro uncertainty that adds near-term risk to the AstraZeneca Pharma India share price target 2026 timeline.

Sector-Specific Risks

Regulatory changes, input cost volatility, and competitive intensity in the Pharma space could pressure margins and delay realisation of the AstraZeneca Pharma India share price target of Rs 11200.

FII Outflows

Continued FII selling in Indian equities could suppress the valuation multiples needed for AstraZeneca Pharma India to reach its analyst price forecast of Rs 11200 within the 12 month horizon.

AstraZeneca Pharma India Financial Snapshot FY25 to FY27

Metric	FY25 Actual	FY26 Estimate	FY27 Estimate
Revenue (Rs Cr)	Refer NSE filing	Refer NSE filing	Refer NSE/BSE filing
EBITDA Margin	Refer NSE filing	Refer NSE filing	Expected expansion
PAT (Rs Cr)	Refer NSE filing	Refer NSE filing	15 to 20 percent growth
Market Cap	Rs 18530 crore	Higher at 52W peak	Tracks price movement
P/E Ratio	48x	Current level	Target implies re-rating
52 Week High / Low	Rs 10200 / Rs 7400

If you want to track AstraZeneca Pharma India financial metrics, analyst ratings and peer comparisons in real time, check the Univest Screener for live data.

Technical Outlook for AstraZeneca Pharma India Share Price

AstraZeneca Pharma India is trading at Rs 8800, currently attempting to build a base above its 52 week low of Rs 7400. The stock needs to reclaim its 200 day moving average to confirm a meaningful recovery trend. The AstraZeneca Pharma India share price target of Rs 11200 set by analysts assumes fundamental delivery over the next 12 months rather than near-term price action. Download the Univest iOS App or Univest Android App to track AstraZeneca Pharma India live price and set alerts.

Conclusion

The AstraZeneca Pharma India share price target 2026 of Rs 11200 reflects analyst conviction on FY27 earnings delivery, structural sector tailwinds, and the favourable domestic macro environment. The bull case of Rs 13400 is achievable if the company executes above expectations. Investors should monitor quarterly earnings, FII ownership trends and management commentary closely. For real-time tracking and research, use the Univest Screener.

This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.

Frequently Asked Questions

What is the AstraZeneca Pharma India share price target for 2026?

The AstraZeneca Pharma India share price target for 2026 is Rs 11200 as per the analyst price forecast, implying 27 percent upside from the current price of Rs 8800. The bull case target is Rs 13400 and the bear case is Rs 6720.

Is AstraZeneca Pharma India a good buy at Rs 8800?

At Rs 8800, AstraZeneca Pharma India trades at a trailing P/E of 48x and offers potential upside to the analyst price forecast of Rs 11200. Whether it is a good buy depends on your investment horizon and risk appetite. Always consult a SEBI registered financial advisor.

What is the 52 week high and low of AstraZeneca Pharma India?

The 52 week high of AstraZeneca Pharma India is Rs 10200 and the 52 week low is Rs 7400. The current CMP of Rs 8800 positions the stock at a meaningful discount to its peak, which is factored into the analyst AstraZeneca Pharma India share price target 2026.

What sector does AstraZeneca Pharma India belong to?

AstraZeneca Pharma India belongs to India’s Pharma sector and trades on NSE with the ticker ASTRAZEN. Track the entire Pharma sector on the Univest Screener.

What is the bull case for AstraZeneca Pharma India share price?

The bull case for AstraZeneca Pharma India share price is Rs 13400, which assumes revenue growth exceeding 25 percent in FY27, margin expansion of 200 basis points, and a positive re-rating of the Pharma sector. This scenario requires strong execution and supportive macro conditions.

What are the key risks to the AstraZeneca Pharma India share price target?

Key risks include earnings miss in upcoming quarters, continued FII selling, regulatory headwinds in the Pharma sector, raw material cost volatility, and global macro uncertainty driven by the US tariff environment. These risks could push the stock toward the bear case of Rs 6720.

Recent Article

Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026